预约演示
更新于：2025-12-21
Nimustine Hydrochloride
盐酸尼莫司汀
更新于：2025-12-21
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C9H14Cl2N6O2 |
InChIKeyKPMKNHGAPDCYLP-UHFFFAOYSA-N |
CAS号55661-38-6 |
关联
11
项与 盐酸尼莫司汀 相关的临床试验JPRN-jRCT2021190003
Phase II multicenter investigator initiated trial of Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomas - Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomas
JPRN-jRCTs021180011
Phase II study of Convection-enhanced delivery of Nimustine Hydrochloride combined with systemic Temozolomide against recurrent gliomas at brainstem - ACNU/CED plus systemic TMZ against recurrent gliomas at brainstem: Phase II study
NCT02698280
Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
100 项与 盐酸尼莫司汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼莫司汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼莫司汀 相关的专利（医药）
登录后查看更多信息
1,038
项与 盐酸尼莫司汀 相关的文献（医药）2025-07-15Future Oncology
Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis
Article
作者: Nie, Jing ; Wang, Simin ; Zhang, Wenfei ; Wu, Jiyong
INTRODUCTION:
Temozolomide combined with radiotherapy has been widely recognized as the first-line treatment for glioblastoma. However, a standard treatment regimen for recurrent glioblastoma after treatment with temozolomide plus radiotherapy is lacking at present. This network meta-analysis aimed to assess and rank the therapeutic efficacy and safety of temozolomide plus radiotherapy combined with 11 other anti-cancer treatments in glioblastoma so as to provide valuable evidence for appropriate clinical decision-making.
METHODS:
Eligible studies investigating the efficacy and safety of temozolomide plus radiotherapy (standard treatment) compared to combination therapies were obtained by searching PubMed, Cochrane Library, and EMBASE. Outcomes included progression-free survival, overall survival, and grade 3-5 adverse events.
RESULTS:
A total of 16 studies were included in this meta-analysis. Except for autologous lymphoid effector cells specific against tumor, galunisertib, and interferon-β, other anti-cancer treatments used in combination with standard treatment resulted in a survival advantage over standard treatment alone. The combination of nimustine with standard treatment performed best in improving overall survival and progression-free survival and exhibited a favorable safety profile, making it the optimal treatment option for recurrent glioblastoma.
CONCLUSION:
After a comprehensive safety analysis, nimustine and lomustine were identified as effective drugs that could be combined with standard treatment.
PROTOCOL REGISTRATION:
www.crd.york.ac.uk/prospero identifier is CRD420251004329.
2025-06-01CANCER SCIENCE
A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG
Article
作者: Yukihiko Sonoda ; Manabu Kinoshita ; Aya Sato ; Yohei Mineharu ; Yoshiki Arakawa ; Toshihiro Kumabe ; Ichiyo Shibahara ; Masayuki Kanamori ; Kenichiro Matsuda ; Kentaro Chiba ; Yasuo Aihara ; Ryuta Saito ; Teiji Tominaga ; Fumiaki Takahashi
ABSTRACT:
Diffuse intrinsic pontine glioma (DIPG) is a very challenging‐to‐treat pediatric malignant tumor, with a median survival time of < 12 months. Convection‐enhanced delivery (CED) allows for direct drug administration into the tumor site, showing potential as a novel therapeutic approach. This study evaluated the efficacy of CED of nimustine hydrochloride (ACNU) in children with DIPG. This phase 2, single‐arm, multicenter study enrolled patients aged 3–21 years and diagnosed with DIPG. The investigational treatment commenced 1 month after completing radiotherapy (local 50–60 Gy). The treatment involved stereotactic brain surgery for catheter placement, followed by ACNU administration via a CED catheter at a concentration of 0.75 mg/mL for 2–3 days until a cumulative dose of 7 (±0.3) mL was achieved. The primary endpoint was the 1‐year survival rate. From April 2018 to March 2020, 21 children were enrolled in the trial and treated, with 20 evaluable for the primary endpoint. The 1‐year survival rate from the start of radiotherapy was 60%, and the median survival time was 15 months. The response rate was analyzed in 20 patients, with one complete response (CR), six partial responses (PR), nine stable diseases, and four progressive diseases, resulting in a response rate of 35% (CR + PR). The CED of ACNU in the brainstem of children with DIPG after radiotherapy appears to be an effective therapeutic strategy. This approach warrants further development as a treatment for children with DIPG. This study is registered with jRCT (No. jRCT2021190003).
2025-03-04British journal of neurosurgery
Spontaneous Shrinkage of isocitrate dehydrogenase (IDH)-mutant astrocytoma caused by intra-tumoural cyst rupture: a case report
Article
作者: Tominaga, Teiji ; Suzuki, Ryutaro ; Watanabe, Mika ; Saito, Ryuta ; Kanamori, Masayuki ; Shimoda, Yoshiteru
BACKGROUND:
T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign is a specific imaging finding of isocitrate dehydrogenase (IDH)-mutant astrocytomas. Histologically, a hypointense area on FLAIR images indicates the presence of microcysts. Here we report a case of IDH-mutant astrocytoma that shrunk spontaneously.
CASE DESCRIPTION:
A 26-year-old woman presented with a complaint of headache. Her magnetic resonance (MR) images revealed a lesion mass with a T2-FLAIR mismatch sign in the left frontal lobe. Subsequently, after 1 month, she was referred to our department, and we found that the lesion had unexpectedly shrunk; however, no further shrinkage was observed in the next 3 months. Furthermore, a biopsy was performed, and the results indicated a diagnosis of astrocytoma, IDH-mutant CNS WHO grade 3. Thus, she underwent subtotal resection. We found no neurological deficits in the patient, and she received 60 Gy of radiotherapy at the local site and chemotherapy with nimustine hydrochloride (ACNU), followed by the administration of ACNU every 8 weeks for 2 years. Overall, after 36 months of tumour resection, she was in good health and exhibited no recurrence. Notably, her histological and MR image findings suggested that the macroscopic cyst was formed by the fusion of microcysts, which is a characteristic feature of IDH-mutant astrocytoma with a T2-FLAIR mismatch sign, and that the tumour shrunk because of the rupture of the cyst in the Sylvian cistern.
CONCLUSION:
The present case report suggests that IDH-mutant astrocytoma cannot be ruled out even when the lesion shrinks spontaneously.
3
项与 盐酸尼莫司汀 相关的新闻（医药）2025-11-11
·医路我伴
上市批准抗体药物偶联物免疫疗法
2025-04-22
·摩熵医药
申请上市抗体药物偶联物临床1期临床申请
2024-02-27
·米内网
上市批准申请上市医药出海核酸药物免疫疗法
100 项与 盐酸尼莫司汀 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性淋巴细胞白血病 | 中国 | 2002-07-25 | |
| 费城染色体阳性慢性粒细胞白血病 | 中国 | 2002-07-25 | |
| 脑癌 | 日本 | 1979-05-22 | |
| 慢性白血病 | 日本 | 1979-05-22 | |
| 结直肠癌 | 日本 | 1979-05-22 | |
| 肝癌 | 日本 | 1979-05-22 | |
| 肺癌 | 日本 | 1979-05-22 | |
| 淋巴瘤 | 日本 | 1979-05-22 | |
| 胃癌 | 日本 | 1979-05-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 21 | 淵鏇膚夢獵選廠衊壓網(衊窪鏇獵鬱膚鏇繭範齋) = 構壓繭蓋醖範餘築獵獵 艱顧憲淵遞襯願鏇膚糧 (憲築構繭齋鏇窪鹽顧衊 ) 更多 | 积极 | 2022-06-02 | |||
临床1/2期 | 7 | 廠鏇艱鑰鑰鬱製鹽襯鏇(網鬱憲獵顧餘顧鑰淵壓) = One in 3 patients who received 0.5 mg/mL developed lacunar infarction 鏇醖觸製鑰醖鑰衊壓網 (齋壓壓壓鹹簾餘鑰膚製 ) | 积极 | 2016-11-07 | |||
临床3期 | 535 | RT/ACNU | 繭鏇鏇艱顧鏇鹹餘觸窪(蓋齋積艱製範窪餘鬱壓) = 膚蓋築製範鏇觸鹽鏇築 獵鑰夢積餘簾構範窪簾 (淵遞鹽構築觸憲壓觸膚 ) | 积极 | 2015-11-09 | ||
RT/TMZ | 繭鏇鏇艱顧鏇鹹餘觸窪(蓋齋積艱製範窪餘鬱壓) = 顧蓋繭鬱淵網構醖鹹觸 獵鑰夢積餘簾構範窪簾 (淵遞鹽構築觸憲壓觸膚 ) | ||||||
临床1/2期 | - | 製選遞醖願淵夢積齋齋(糧鹽製遞壓窪壓願構艱) = Acute toxicity was mainly hematologic and was controllable 鹹衊鬱餘鏇願壓鹽願廠 (夢齋鹹遞衊鏇糧鹹襯顧 ) 更多 | 积极 | 2009-11-01 | |||
N/A | 151 | 鹹糧廠觸壓艱網範鏇觸(膚鏇願築糧範繭鬱廠繭) = 繭鑰鹽廠範網壓壓醖齋 遞簾憲廠壓襯窪餘窪憲 (網簾繭膚鹹遞憲襯壓廠 ) | 积极 | 2008-05-20 | |||
N/A | 35 | 襯鏇蓋鏇蓋糧獵糧艱餘(膚艱餘醖糧夢鏇襯蓋顧) = 築鏇鏇範顧淵積鬱鏇壓 襯構觸淵膚鏇糧鬱範鹹 (壓願網鏇製觸艱製夢構 ) 更多 | 积极 | 2008-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用